Spotlight On... Shire to take on hemophilia marketing with long-sought Baxalta buy; Walgreens eyes more specialty deals with drugmakers; Sanofi Pasteur's new commercial SVP to keep current agencies; and more...

Baxalta ($BXLT) and its portfolio of hemophilia meds are finally destined to join the fold at Shire ($SHPG). Monday, the two companies announced a $32 billion tie-up after a months-long pursuit by the Dublin drugmaker. More from FiercePharma

> Walgreens ($WBA) it's looking at follow-up specialty pharmacy deals with drugmakers, now that it has sealed a pact with troubled Valeant Pharmaceuticals ($VRX) on a slate of its meds. Report

> Sanofi Pasteur tapped David Loew as its new SVP for global commercial operations; the French drugmaker said its agency relationships won't change, nor will its commercial strategy. Report

> Swedish Orphan Biovitrium said Elocta, a long-acting hemophilia A treatment it developed with Biogen ($BIIB), has been launched in Europe. Release

> Valneva said its Japanese encephalitis vaccine won approval in Taiwan through its partner there, Adimmune. Report

And Finally... A large new study, published in the BMJ, found no risk of birth defects from oral contraceptives. Report

Suggested Articles

Changing adult healthcare habits is difficult, but GSK's general vaccine awareness campaign begun this summer reports early successes.

Pharma companies have joined the “get out the vote” trend this election by giving time off to vote and encouraging volunteering at the polls.

Sanofi and Regeneron released follow-up data from a phase 3 trial for immunology blockbuster Dupixent in an eosinophilic esophagitis.